Clinical trials
Resectable Intrahepatic Cholangiocarcinoma clinical trials
Below are recruiting resectable intrahepatic cholangiocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 49 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06923475RecruitingPhase 2/Phase 3
Chemo plus immunotherapy before surgery for bile duct cancer
This trial tests whether giving chemotherapy (gemcitabine and cisplatin) combined with immunotherapy (pembrolizumab) before and after surgery can improve outcomes compared to having surgery right away. It is for people with bile duct cancer that can be removed or is borderline removable.
AmsterdamAges 18 years+ - NCT06192797RecruitingPhase 2
Combination therapy for unresectable bile duct cancer
This trial tests a combination of three treatments—a liver-directed chemotherapy infusion (HAIC), a targeted therapy pill (lenvatinib), and an immunotherapy (pucotenlimab)—to try to shrink bile duct cancers that cannot be surgically removed. The goal is to make the cancer surgically removable or to control it for as long as possible.
Wuhan, HubeiAges 18 years+ - NCT04078230Recruiting
Extending lymph node removal during liver tumor surgery
This study looks at whether removing more lymph nodes while surgically removing an intrahepatic cholangiocarcinoma (bile duct cancer in the liver) improves outcomes. It may help by better checking and treating possible microscopic spread to lymph nodes.
Baltimore, MarylandAges 18–80 - NCT04299581RecruitingPhase 2
Freezing treatment plus immunotherapy for advanced bile-duct cancer
This Phase 2 trial tests whether freezing part of the liver tumor (cryoablation) combined with an immunotherapy drug called anti–PD-1 can shrink advanced bile-duct cancer that can’t be removed by surgery. It may help control the cancer after prior treatments have stopped working.
ShanghaiAges 18 years+ - NCT04556214Recruiting
Liver transplant test for certain bile duct cancers
This trial studies whether a liver transplant can help people with a non-removable type of bile duct cancer in the liver. To be eligible, the cancer must be in the liver only (no spread), and you typically must already have had at least 6 months of treatment before being listed for transplant.
OsloAges 18 years+ - NCT04954781RecruitingPhase 2
Chemo plus immunotherapy for advanced bile duct liver cancer
This Phase 2 trial tests whether a procedure called TACE combined with the immunotherapy drug tislelizumab can shrink advanced bile duct liver cancer and help you live longer. It is for people whose cancer cannot be removed and has progressed after at least one prior treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05655949RecruitingPhase 2
Y-90 radiation plus immunotherapy and chemo for bile duct cancer
This trial studies whether combining Y-90 liver radiation with an immunotherapy drug (durvalumab) and chemo (gemcitabine and cisplatin) can better control locally advanced or metastatic intrahepatic cholangiocarcinoma (bile duct cancer in the liver). It may help shrink tumors and slow disease growth, depending on how well the treatment works for your cancer type and overall health.
Boston, MassachusettsAges 18 years+ - NCT05678270RecruitingPhase 2
ICP-192 for FGFR2 fusion bile duct cancer that spread
This Phase 2 trial tests a medicine called ICP-192 in people with intrahepatic bile duct cancer that cannot be removed with surgery and has spread. It is for tumors that have an FGFR2 fusion/rearrangement, especially after prior chemotherapy stopped working.
Hefei, AnhuiAges 18 years+ - NCT05967182RecruitingPhase 2
Pembrolizumab plus chemo before or around liver surgery
This trial tests whether pembrolizumab combined with gemcitabine and cisplatin given around the time of surgery can improve outcomes for people with high-risk, potentially operable intrahepatic cholangiocarcinoma (bile duct cancer in the liver). It may help by strengthening the immune system while also treating the cancer with chemotherapy.
Houston, TexasAges 18 years+ - NCT06058663RecruitingPhase 1
Radiation and immunotherapy for advanced bile duct cancer
This trial tests combining a targeted radiation treatment (radioembolization) with two immunotherapy drugs (tremelimumab and durvalumab) for people with advanced intrahepatic cholangiocarcinoma that cannot be removed by surgery. It aims to shrink tumors and control cancer spread to lymph nodes or one other organ.
Jacksonville, FloridaAges 18 years+ - NCT06098547Recruiting
Liver transplant for bile duct cancer that can't be removed
This trial tests if a liver transplant can help people with a certain type of bile duct cancer (intrahepatic cholangiocarcinoma) that cannot be surgically removed. You must have had at least six months of chemotherapy and your cancer must be stable or smaller before you can be listed for a transplant.
PadovaAges 18–70 - NCT06140134Recruiting
Liver transplant for bile duct cancer that hasn't spread
This study tests if a liver transplant can help people with a type of bile duct cancer that can't be removed with surgery. You may join if the cancer has stayed stable or shrunk for at least 6 months with treatment.
Newark, New JerseyAges 18–89 - NCT06208462RecruitingPhase 2
Combination therapy before surgery for high-risk bile duct cancer
This trial tests a combination of chemotherapy directly into the liver artery, an immunotherapy drug, and a targeted therapy pill before surgery for a type of bile duct cancer that has a high chance of coming back. The goal is to see if this approach can improve outcomes for patients whose cancer is still removable but has certain high-risk features.
Nanjing, JiangsuAges 18–75 - NCT06296563RecruitingPhase 2
Testing adebrelimab, apatinib, and HAIC for bile duct cancer
This trial tests if adding a combination of immunotherapy (adebrelimab), a targeted drug (apatinib), and chemotherapy into the liver artery (HAIC) before and after surgery can help people with resectable intrahepatic cholangiocarcinoma (a type of bile duct cancer). The goal is to see if this approach improves outcomes.
Jinan, ShandongAges 18 years+ - NCT06313203RecruitingPhase 2
Chemotherapy with or without liver-directed treatment for bile duct cancer
This trial tests whether adding a liver-directed treatment (HAI floxuridine or SIRT) to standard chemotherapy (GemOx) is more effective for people with bile duct cancer inside the liver that cannot be removed by surgery. It may be an option for those whose cancer is only in the liver or nearby lymph nodes.
Oslo, OsloAges 18 years+ - NCT06406816RecruitingEarly Phase 1
Vaccine and chemotherapy after surgery for bile duct cancer
This trial tests a personalized cancer vaccine combined with chemotherapy to help prevent bile duct cancer from coming back after surgery. It is for people who had their tumor removed but have a high risk of recurrence.
Fuzhou, FujianAges 18–75 - NCT06664021RecruitingPhase 2
Tislelizumab and S-1 for recurrent high-risk bile duct cancer
This trial tests a combination of two drugs (tislelizumab and S-1) for people whose bile duct cancer has come back after surgery and had high-risk features. The goal is to see if this treatment can help control the cancer.
Fuyang, AnhuiAges 18–75 - NCT06721286RecruitingPhase 2
Combining immunotherapy with chemotherapy before surgery for bile duct cancer
This trial tests whether adding an immunotherapy drug (toripalimab) to standard chemotherapy before surgery can improve outcomes for people with intrahepatic cholangiocarcinoma that can be surgically removed. It's for patients who haven't had prior treatment for their cancer and are in good overall health.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06888063RecruitingPhase 2
Chemo pump into the liver for bile duct cancer that can be surgically removed
This trial tests whether giving extra chemotherapy directly to the liver through a small pump (called HAIP) before or after surgery can improve outcomes for patients with bile duct cancer inside the liver. It is for patients whose cancer is considered removable by surgery.
Rotterdam, South HollandAges 18 years+ - NCT07063888RecruitingPhase 2
Chemoradiation after surgery for bile duct cancer
This trial tests whether combining chemotherapy with radiation after surgery can help prevent the return of intrahepatic cholangiocarcinoma, a type of bile duct cancer. It is for people whose surgery showed a narrow margin or cancer in nearby lymph nodes.
BeijingAges 18–80 - NCT07070700RecruitingPhase 2
Cryoablation with targeted therapy and immunotherapy for advanced bile duct cancer
This trial tests a combination of cryoablation (freezing tumors), lenvatinib (a targeted therapy), and QL1706 (an immunotherapy) for people with advanced intrahepatic cholangiocarcinoma (bile duct cancer) that has worsened after initial treatment. The goal is to see if this combination can help stop the cancer from growing.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06050252RecruitingPhase 2
Durvalumab plus chemo before surgery for high-risk bile duct cancer
This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy (gemcitabine and cisplatin) before surgery helps people with a high-risk type of bile duct cancer live longer. If you qualify, you would receive the drug combination before your planned surgery.
Irvine, CaliforniaAges 18 years+ - NCT06858735RecruitingPhase 2
HYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Advanced Intrahepatic Cholangiocarcinoma
Phase 2 trial evaluating systemic therapy ± liver-directed RT for advanced intrahepatic cholangiocarcinoma, with broad eligibility for patients who have received at least 4 cycles of gem/cis/durvalumab.
Houston, TexasAges 18 years+ - NCT05286814RecruitingPhase 2
Pump-delivered therapy plus chemo for liver-metastatic cancers
This phase 2 study tests a liver-targeted medicine delivered through a special implanted pump, combined with standard chemo, for cancers that spread mainly to the liver. It may help control tumor growth in the liver and improve outcomes compared with standard treatment alone.
Bethesda, MarylandAges 18–120
Hear when a new Resectable Intrahepatic Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for resectable intrahepatic cholangiocarcinoma?
- Yes. Clin2 currently lists 49 recruiting resectable intrahepatic cholangiocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a resectable intrahepatic cholangiocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a resectable intrahepatic cholangiocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.